The recent demonstration that intranasal administration of an engineered IgM can improve efficacy, reduce resistance and simplify the prophylactic and therapeutic treatment of COVID-19 in mice strongly suggests that enhancing the human IgM response or administering engineered IgM could significantly prevent SARS-CoV-2 infection and improve outcome (241). Here, CD40LG is linked to COVID-19.